This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may speed up how quickly your liver processes your cancer medicine.
What might happen:
The amount of your cancer medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to adjust the dose of your cancer medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Bosulif (bosutinib) US prescribing information. Pfizer Inc. November, 2016.
2.Cometriq (cabozantinib) US prescribing information. Exelixix, Inc. May, 2016.
3.Zykadia (ceritinib) US prescribing information. Novartis Pharmaceuticals Corporation July, 2015.
4.Xalkori (crizotinib) US prescribing information. Pfizer Inc. April, 2016. 5.Tafinlar (dabrafenib) US prescribing information. GlaxoSmithKline June, 2016.
5.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company August, 2015.
6.Tarceva (erlotinib) US prescribing information. Genentech, Inc. October, 2016.
7.Iressa (gefitinib tablets) US prescribing information. AstraZeneca Pharmaceuticals LP April 7, 2004.
8.Imbruvica (ibrutinib) US Prescribing information. Pharmacyclics, Inc. June, 2016.
9.Zydelig (idelalisib) US prescribing information. Gilead Sciences, Inc. July, 2014.
10.Gleevec (imatinib mesylate) US prescribing information. Novartis Pharmaceuticals Corporation October, 2013.
11.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline October, 2013.
12.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation November, 2016.
13.Votrient (pazopanib) US prescribing information. GlaxoSmithKline May, 2016.
14.Nexavar (sorafenib) US prescribing information. Bayer Pharmaceuticals Corporation November, 2013.
15.Sutent (sunitinib malate) US prescribing information. Pfizer Inc. April, 2015.
16.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP July, 2016.
17.Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004 Feb;53(2):102-6.
18.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
19.Cabometyx (cabozantinib) tablets, US prescribing information. Exelixis Inc. April 25, 2016.
20.Ohgami M, Kaburagi T, Kurosawa A, Homma M. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer. Lung Cancer 2016 Nov;101:9-10.
21.Abbas R, Boni J, Sonnichsen D. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metab Pers Ther 2015 Mar;30(1):57-63.